News Releases

Archives: Search / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013

2012201120102009200820072003

Oct 16, 2019

Nektar Therapeutics (NASDAQ: NKTR) today announced the initiation of a first-in-human, Phase 1 clinical study evaluating NKTR-255, an interleukin-15 (IL-15) receptor agonist, as monotherapy for...

More
Oct 7, 2019

Nektar Therapeutics (NASDAQ: NKTR) today announced the initiation of two Phase 1b studies of NKTR-358 (LY3471851*), a novel T regulatory (Treg) cell stimulator, one in patients with psoriasis and...

More
Oct 2, 2019

Nektar Therapeutics (Nasdaq: NKTR) today announced the acceptance of five clinical and preclinical data abstracts for its immuno-oncology portfolio at the 2019 Society for Immunotherapy of Cancer...

More
Oct 1, 2019

Nektar Therapeutics (Nasdaq: NKTR) announced today several promotions on its executive leadership team: Jonathan Zalevsky, Ph.D. has been promoted to Chief Research & Development Officer Gil M....

More
Sep 26, 2019
Analyst conference call with breast cancer specialist to be held at 2:30 p.m. Central European Summer Time (CEST)/8:30 a.m. Eastern Daylight Time (EDT) today

Nektar Therapeutics (Nasdaq: NKTR) announced today a presentation of new clinical data for bempegaldesleukin (bempeg, NKTR-214) in combination with nivolumab in patients with advanced or...

More
 

 
 
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide